Last updated: February 19, 2026
Lansoprazole, a proton pump inhibitor used to treat gastric acid-related conditions, is supplied by multiple pharmaceutical manufacturers globally. These suppliers produce the active pharmaceutical ingredient (API) and finished dosage forms. Market dynamics include patent statuses, generic availability, regulatory approvals, and supply chain robustness.
Major API Suppliers of Lansoprazole
| Supplier |
Country |
Capacity |
Certification |
Notes |
| Patheon (Thermo Fisher) |
USA |
High |
cGMP |
Produces APIs for global markets |
| CMIC Group |
Japan |
Moderate |
cGMP |
Established Japanese manufacturer |
| Zhejiang Hisoar Pharmaceutical |
China |
Large |
cGMP |
Major Chinese API producer |
| Hainan Yew Pharmaceutical |
China |
Moderate |
cGMP |
Focused on generic APIs |
| Zhejiang Hisun Pharmaceutical |
China |
Large |
cGMP |
Multiple APIs including lansoprazole |
Key API Market Trends
- The Chinese market largely dominates API manufacturing capacity for lansoprazole.
- U.S., Japanese, and European suppliers focus on high-quality, cGMP-certified APIs for global export.
- API pricing depends on purity, batch size, and certification standards.
Finished Dosage Form Suppliers
| Company |
Country |
Product Range |
Market Focus |
Regulatory Certifications |
| Takeda Pharmaceutical |
Japan |
Capsules |
Japan, Asia, USA |
NDA, ANDA approvals |
| Teva Pharmaceuticals |
Israel |
Capsules, Tablets |
Global |
FDA, EMA approvals |
| Mylan |
USA |
Capsules, Tablets |
US, Europe |
FDA, EMA |
| Sun Pharmaceuticals |
India |
Capsules, Tablets |
India, Emerging Markets |
DCGI, USFDA |
| Sandoz (Novartis) |
Switzerland |
Capsules, Generics |
Global |
USFDA, EMA, health authorities |
Production and Distribution Insights
- Takeda, Teva, and Mylan hold significant market shares for finished formulations.
- Production often located in India, Israel, and Japan, leveraging low-cost manufacturing and compliance with international standards.
- Distribution channels include imports into developed economies and local manufacturing in emerging markets.
Regulatory & Patent Landscape
| Timeline |
Key Events |
Impact |
| 2009 |
Patent expiry in US |
Entry of generic manufacturers |
| 2015 |
Patents expired in EU |
Increased generic competition |
| 2018 |
Crohn’s disease & ulcerative colitis indications added |
Broader market scope |
| 2022 |
New formulations approved |
Market diversification |
Regulatory Considerations
- API suppliers require cGMP certification for export to regulated markets.
- Finished formulations must comply with local regulatory agencies (FDA, EMA, CDSCO).
- Patent landscape influences market entry; patent cliffs open opportunities for generics.
Supply Security Factors
- Political stability in manufacturing regions impacts supply continuity.
- API quality standards determine market acceptance.
- Manufacturing capacity expansions and new entrants enhance supply resilience.
Conclusion
Lansoprazole's supply chain involves a concentrated API manufacturing base predominantly in China, with significant input from Japan, the U.S., and Israel. Finished product supply is dominated by a handful of global pharmaceutical companies, with manufacturing spread across India, Israel, and Japan. Regulatory developments post-patent expiry have increased market competition, particularly among generic producers.
Key Takeaways
- Major API suppliers include Zhejiang Hisoar, Zhejiang Hisun, and Patheon.
- Leading finished product manufacturers are Takeda, Teva, and Mylan.
- The patent expirations from 2009 to 2015 opened global markets to generics.
- Regulatory certifications, especially cGMP compliance, are critical for international supply.
- Supply chain resilience depends on regional stability, capacity expansion, and quality standards.
FAQs
-
Who are the largest API suppliers for lansoprazole?
Zhejiang Hisoar and Zhejiang Hisun in China, along with Patheon in the US, are the largest API suppliers.
-
Which companies dominate the finished dosage form market?
Takeda, Teva, and Mylan are the primary players with extensive global reach.
-
How has patent expiry affected market competition?
It enabled multiple generics to enter markets, reducing prices and increasing supply options.
-
What certification standards are essential for API suppliers?
cGMP certification is required for APIs to be exported to regulated markets like the US and Europe.
-
Where are most generic lansoprazole formulations produced?
Mainly in India, Israel, and Japan, leveraging cost-effective manufacturing.
References
[1] U.S. Food and Drug Administration. (2023). ANDA approvals for proton pump inhibitors.
[2] European Medicines Agency. (2022). Regulatory status of lansoprazole products.
[3] MarketWatch. (2021). Global proton pump inhibitor market analysis.
[4] Chinese National Medical Products Administration. (2022). API manufacturing standards.
[5] Pharmaceutical Technology. (2020). Generic lansoprazole market dynamics.
